← Leaderboards
Jing-Ruey Joanna Yeh
Massachusetts General Hospital
$6,608,932
Attributed
$8,318,985
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $972.6K · FY2008–22$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,318,985 · 5
By mechanism
R01$6,131,368 · 3
U01$1,525,577 · 1
K01$662,040 · 1
Top collaborators
- David Kokel4 shared
- Randall T Peterson4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Randall T Peterson$17,953,472
- Calum A. Macrae$21,291,852
- Stephen N. Gomperts$8,663,513
- Anders M Naar$8,178,903
- Changning Wang$11,415,964
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoCellsMutationPhenotypeIn VitroGenesZebrafishBaseChemical GeneticsResearch StudyMutantSmall MoleculeLeadDefectLeukemia, Myelocytic, AcuteAnimal ModelAml1-Eto Fusion ProteinGenomeMalignant NeoplasmsChromosomal TranslocationHematopoietic Stem CellsInsightFishesEmbryo
Grant awards (23)
Targeting ROS production in OXPHOS-defective and OXPHOS-competent tumors$486,702
R01 · FY2022 · CA · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$470,351
R01 · FY2022 · GM
Targeting ROS production in OXPHOS-defective and OXPHOS-competent tumors$496,635
R01 · FY2021 · CA · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$470,351
R01 · FY2021 · GM
Targeting ROS production in OXPHOS-defective and OXPHOS-competent tumors$502,229
R01 · FY2020 · CA · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$470,351
R01 · FY2020 · GM
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$483,476
R01 · FY2019 · GM
Targeting ROS production in OXPHOS-defective and OXPHOS-competent tumors$481,735
R01 · FY2019 · CA · contact PI
Targeting ROS production in OXPHOS-defective and OXPHOS-competent tumors$513,278
R01 · FY2018 · CA · contact PI
Scalable in vivo tools for annotating and manipulating the druggable genome$448,950
U01 · FY2016 · MH · contact PI
Scalable in vivo tools for annotating and manipulating the druggable genome$448,950
U01 · FY2015 · MH · contact PI
Scalable in vivo tools for annotating and manipulating the druggable genome$174,000
U01 · FY2015 · MH · contact PI
Scalable in vivo tools for annotating and manipulating the druggable genome$453,677
U01 · FY2014 · MH · contact PI
Discovering chemical tools for acute myelogenous leukemia$345,570
R01 · FY2014 · CA · contact PI
Discovering chemical tools for acute myelogenous leukemia$334,882
R01 · FY2013 · CA · contact PI
Discovering chemical tools for acute myelogenous leukemia$356,257
R01 · FY2012 · CA · contact PI
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia$132,570
K01 · FY2012 · AG · contact PI
Discovering chemical tools for acute myelogenous leukemia$354,907
R01 · FY2011 · CA · contact PI
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia$132,570
K01 · FY2011 · AG · contact PI
Discovering chemical tools for acute myelogenous leukemia$364,644
R01 · FY2010 · CA · contact PI
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia$132,570
K01 · FY2010 · AG · contact PI
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia$132,570
K01 · FY2009 · AG · contact PI
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia$131,760
K01 · FY2008 · AG · contact PI